Peptide Regulatory Landscape
The peptide regulatory landscape shifted significantly in early 2026. Following HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement, approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list are being returned to Category 1, restoring legal compounding access through licensed pharmacies with a physician's prescription. The FDA continues to refine its approach to compounded peptides under the FD&C Act, and state boards of pharmacy and medicine continue to issue their own guidance. Providers must stay current on federal rules, the 503A/503B framework, and state-specific restrictions to maintain compliant practices.
Last updated: June 8, 2026
Active Regulatory Alerts
STAT+: Medicare still won't say how much covering obesity drugs will cost
As Medicare prepares to offer Wegovy and Zepbound to eligible seniors at a $50 monthly copay beginning July 2026, the agency continues to withhold any public cost estimates for the program. The absence of fiscal projections has drawn criticism from budget watchdogs and lawmakers who argue taxpayers deserve transparency before the rollout begins. The situation underscores broader tensions surrounding large-scale public coverage of high-cost GLP-1 receptor agonist therapies.
Source: STAT News
Read moreSTAT+: Medicare's mum on GLP-1s, and Massachusetts sues United
Medicare has declined to disclose cost projections related to its newly announced coverage of GLP-1 obesity medications for seniors at a $50 monthly cap. The lack of transparency raises significant questions about federal budget exposure as the program is set to launch in July 2026. Policy analysts and advocates continue to press the agency for estimates that could shape future drug pricing and coverage decisions.
Source: STAT News
Read moreAstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
The European Medicines Agency issued a positive opinion for Novo Nordisk's oral Wegovy formulation, marking a significant regulatory milestone for GLP-1 receptor agonist therapy in a new delivery format. The EU approval of an oral semaglutide weight management option expands patient access options beyond injectable formulations currently dominant in the market. This development signals continued momentum for GLP-1 based therapies in major global markets even as regulatory bodies occasionally diverge in their assessments.
Source: Endpoints News
Read moreSTAT+: Maryland state affordability board places a price cap on Ozempic
Maryland's prescription drug affordability board has set a price cap on Ozempic, marking a significant move among the nine states pursuing similar affordability measures for high-cost medications. The decision represents a direct state-level intervention in the pricing of semaglutide, one of the most widely prescribed GLP-1 receptor agonists in the United States. This action could serve as a precedent for other states seeking to regulate the cost of GLP-1 therapies and related peptide-based treatments.
Source: STAT News
Read moreA new Medicare option for weight loss drugs is coming: Here's what to know
Medicare is preparing to offer millions of eligible beneficiaries access to discounted GLP-1 receptor agonist medications for weight loss through a new cost-sharing program, representing a significant expansion of federal coverage for peptide-based obesity therapies. The policy development marks a pivotal shift in how the United States government approaches pharmacological obesity treatment at scale. Healthcare advocates note that improved affordability could substantially increase patient uptake of GLP-1 drugs among older Americans.
Source: NPR Health
Read moreSTAT+: FDA wants to exclude weight loss drugs from a compounding list
The FDA is moving to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing the end of drug shortages from Novo Nordisk and Eli Lilly as the primary justification. This action would effectively halt outsourcing facilities from legally producing bulk compounded versions of these widely used GLP-1 receptor agonists. The proposed rule represents a pivotal moment for compounding pharmacies that have built significant operations around these medications.
Source: STAT News
Read moreSTAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA
Surgeon general nominee Dr. Nicole Saphier has expressed notable views on peptides as part of her broader positions on health, diet, and emerging therapies, drawing attention from the medical and regulatory community. Her nomination places someone with documented interest in peptide-related treatments in a position of significant public health influence. Stakeholders in the peptide therapy space are closely monitoring her past statements for signals about future policy priorities.
Source: STAT News
Read moreCourt dismisses part of Lilly lawsuit against Empower, some claims can proceed
A federal judge has partially dismissed Eli Lilly's lawsuit against Empower Pharmacy over compounded tirzepatide, while allowing several of Lilly's core claims to move forward. The case centers on allegations that Empower misled consumers about its compounded versions of the blockbuster obesity drug. The ruling carries significant implications for the compounding pharmacy industry and the ongoing legal landscape surrounding GLP-1 receptor agonist compounding.
Source: Endpoints News
Read moreFDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
The FDA has formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, determining that no sufficient clinical need exists for outsourcing facilities to compound these drugs from bulk substances. The proposal follows the resolution of documented drug shortages and reflects the agency's position that commercially manufactured versions adequately serve patient demand. This regulatory action could have sweeping consequences for the compounding industry and patient access to lower-cost alternatives.
Source: FDA
Read moreOpinion: STAT+: Did Kennedy just stack the deck on FDA oversight of peptides?
A significant shift in FDA oversight of peptides may be underway following signals from Health and Human Services Secretary Robert F. Kennedy Jr. regarding upcoming policy changes affecting the regulatory landscape for peptide therapies. The move has drawn considerable attention from compounding pharmacies, peptide manufacturers, and clinicians who rely on access to peptide-based treatments. Analysts are closely watching how any restructuring of FDA authority could reshape the approval pathway and availability of both compounded and commercially developed peptides.
Source: STAT News
Read moreHHS Reclassifies 14 Peptides From Category 2 Back to Category 1
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list will be moved back to Category 1. Affected peptides include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. Licensed 503A compounding pharmacies may once again prepare these peptides pursuant to a valid physician prescription. Reclassification does NOT mean the peptides are FDA-approved drugs — the 503A framework, documentation, and medical-necessity requirements still apply.
Source: HHS / FDA
FDA Clarifies Compounded GLP-1 Policy and 'Essentially a Copy' Standard
On April 1, 2026, the FDA issued clarifying guidance reminding 503A pharmacies and 503B outsourcing facilities that compounded drugs qualify for the FD&C Act statutory exemptions only when applicable conditions are satisfied — with specific focus on the 'essentially a copy' standard. Because the tirzepatide shortage was resolved in December 2024 and the semaglutide shortage in February 2025, compounders preparing GLP-1 analogues must document clinical-difference justification for each patient and should review their 'essentially a copy' analysis.
Source: FDA.gov
GLP-1 Shortages Resolved — Wind-Down Period Enforcement
The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Compounding under shortage provisions has ended, and phased enforcement grace periods have expired. 503A pharmacies may continue patient-specific compounding only where a documented clinical difference justifies it (not as an essential copy of the commercial product). Providers should verify each prescription meets the 'essentially a copy' standard.
Source: FDA Drug Shortage Database
DEA Scheduling Considerations for Peptide Practices
While most therapeutic peptides are not scheduled substances, providers should be aware that certain peptide hormones (e.g., synthetic growth hormone analogues) may trigger DEA scrutiny depending on intended use. Maintain thorough documentation of medical necessity for all peptide prescriptions.
Source: DEA Diversion Control
Join 1,000+ Members in Our Community
Connect with patients, health enthusiasts, and providers discussing peptide therapy, regulatory updates, and the latest research.
Join the CommunityLegal Disclaimer
This page is for educational and informational purposes only and does not constitute legal or regulatory advice. Regulatory requirements change frequently. Providers should consult with qualified legal counsel and verify current regulations with the FDA, their state board of medicine, and state board of pharmacy before making compliance decisions.